Rox Anderson, M.D., FAAD, is Professor in Dermatology, Director of the Wellman Center for Photomedicine, and Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in dermatology. These include selective photothermolysis for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal. He also contributed to laser lithotripsy, laser angioplasty, photodynamic therapy, infrared confocal microscopy. Dr. Anderson has contributed to basic knowledge of human photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions.

Dr. Anderson graduated from MIT, received his M.D. degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology, and completed his residency in dermatology and research fellowships at Harvard.

Dr. Anderson is a past trustee of Advancing Innovation in Dermatology, having helped co-found the organization.

Angela M. Christiano, PhD, is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics and Development at Columbia University Medical Center. She is also the Director of Basic Science Research in the Department of Dermatology at CUMC. For the past 20 years, Dr. Christiano's research has focused on understanding the molecular processes that lead to inherited skin and hair disorders in humans. Her research career began with the discovery of genetic mutations associated with epidermolysis bullosa, a skin disease that causes severe blistering. Dr. Christiano's recent work has focused on the investigation of the underlying genetic causes of and identification of potential therapies for alopecia areata, an autoimmune form of hair loss. She has published more than 300 papers in peer-reviewed journals and has trained more than 50 postdoctoral researchers and clinical fellows at Columbia University through the Program in Genetics & Development, the Institute of Human Nutrition, the Integrated Program in Cellular, Molecular and Biomedical Studies in the Graduate School of Arts & Sciences, the Clinical and Translational Science Award Program, the Stem Cell Training Program.

Dr. Christiano has received numerous awards, including the New York City Mayor's Award for Excellence in Science and Technology – Young Investigator's Award, Columbia University's Harold and Golden Lamport Research Award for Excellence in Clinical Sciences, the CERIES Research Award, and the North American Hair Research Society's award for Outstanding Paper of the Year, the Montagna Award from the Society for Investigative Dermatology, and the Ebling Award from the European Hair Research Society. Dr. Christiano is a prolific inventor and serial entrepreneur, having filed numerous patents on her discoveries, and successfully moved technologies from the academic setting into the commercial sector. She has co-founded several companies in the dermatology space, including Skinetics Bioscience (RNAi-based dermatology therapeutics, acquired by Sirna Therapeutics, which was acquired by Merck & Co. in 2007), Vixen Pharmaceuticals (JAK inhibitors for treatment of hair disorders, acquired by Aclaris Therapeutics in 2016), and Rapunzel Bioscience, focused on regenerative therapies and stem cell approaches for skin and hair disorders.

Dr. Christiano is currently President of the Society for Investigative Dermatology, and serves as Deputy Editor of the Journal of Investigative Dermatology. She earned her MS and PhD degrees in Microbiology and Molecular Genetics from Rutgers University.

Dr. Neil Kumar, Ph.D., is the CEO and Founder of BridgeBio Pharma, LLC, a company focused on the development of novel therapies for rare genetic disorders. Prior to that, he was a principal at Third Rock Ventures where he supported and managed various portfolio companies in addition to focusing on new company formation and due diligence. He also held the role of Vice President, Business Development and Operations for MyoKardia.

Prior to joining Third Rock, Dr. Kumar was an associate principal at McKinsey & Company, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s personalized medicine efforts. Before joining McKinsey, Dr. Kumar was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Dr. Kumar is the author of several peer-reviewed papers in the fields of oncology and systems biology.

Dr. Kumar holds B.S. and M.S. degrees in chemical engineering from Stanford University, and a Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

Raymond A. Miller is a partner and co-chair of the Intellectual Property Department of Pepper Hamilton LLP, resident in the Pittsburgh office. Mr. Miller is co-chair of the firm’s Life Sciences practice group and a member of the firm’s Executive Committee. A registered patent attorney, Mr. Miller focuses his practice on identifying, protecting, securing and maximizing the value of clients’ intellectual property.

Mr. Miller’s clients include universities, research institutes and businesses ranging from idea stage through Fortune 500 companies, as well as other organizations and individuals involved in basic research and technology transfer. He has represented Ivy League universities, research organizations, pharmaceutical companies, biotechnology companies, consumer products companies, manufacturing companies, computer software developers and R&D contractors. His practice includes both prosecution and transactional IP, including acquiring and licensing patents, trademarks, copyrights and trade secrets, as well as litigation.

Mr. Miller’s practice includes an array of chemical, medical, pharmaceutical, mechanical, environmental and business method fields. While he is particularly adept at handling technologies in the life sciences, he also is proficient in areas of material sciences, metallurgy, thin-film technology, specialty chemicals, polymer chemistry, nanotechnology and cosmetics.

Mr. Miller is a member of the American Association for the Advancement of Science, the Association of University Technology Managers, Inc. and the American Intellectual Property Law Association. He has written and presented numerous scientific and legal publications.

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Dr. Piacquadio is the Founder and CEO/President of Therapeutics, Inc. He has been active in clinical research and medical product development since 1985, when he worked as the Director of Research and Development for Oncotherm, a biotechnology company in the field of hyperthermia where his responsibilities included regulatory affairs and clinical development. Since that time, he has started the clinical research program for the Division of Dermatology, University of California, San Diego. From 1989 to 1997, he served as Director of this organization, which became regarded as one of the leading academic product development groups in the United States. In 1997 he started Therapeutics, Inc as a research and development business dedicated to the field of dermatology serving the needs of the biotechnology, pharmaceutical and investment community.

Dr. Piacquadio has also actively participated in the development of a wide variety of biotechnology start-ups and medical product development programs. He has been instrumental in the pre-clinical and clinical development phase of a variety of soft tissue augmentation products including Hylaform® (Biomatrix) and was instrumental in regulatory strategy and clinical development of the first laser based hair removal technology pioneered by Thermolase among others. As a consultant for the FDA Generic Drug Group he assisted in the development of the current bioequivalency standards for topical steroids. Presently he serves in an advisory capacity for a variety of biotechnology and pharmaceutical companies.

Dr. Piacquadio received his B.S. degree in Biomedical Engineering from Rensselaer Polytechnic Institute and received his medical degree from the University of Pennsylvania. He received his graduate clinical training at Brown University as an intern in Internal Medicine and his Dermatology training at University of California, San Diego.

Michael Sierra, Ph.D. is currently Vice President of LEO Science & Tech Hub Cambridge (USA). Prior to this position, he held the positions of Director of Medicinal Chemistry, Director of Chemical Research, Director of External Discovery and Executive Director of Translational Research at LEO Pharma (Denmark). Before that, Michael worked 10 years at GlaxoSmithkline’s Centre de Recherche, Les Ulis (France) and the biotech, CareX, Strasbourg (France) as Head of Chemistry. He received his BS in chemistry from Ohio Northern University (USA), his Ph.D. in chemistry at Wayne State University (USA) and held a 2 year post doctoral position at Ecole Polytechnique, Palaiseau (France). He has 24 years of drug discovery experience in the therapeutic areas of cardiovascular and metabolic diseases as well as inflammation and dermatology with the identification of 18 clinical candidates.

Patricia Walker, MD, PhD, currently serves as the President and Chief Scientific Officer of Brickell Biotech. She is also on the Supervisory Board of Directors for Merz Pharma. Dr. Walker’s professional experience includes her position as Chief Medical Officer of Kythera Biopharmaceuticals, Inc., from May 2007 until March 2013. Then, from 2004 to 2007, Dr. Walker served as Executive Vice President and Chief Science Officer at Allergan Medical (formerly known as Inamed Corporation). Prior to that experience, from 1997 to 2004, Dr. Walker held positions of increasing responsibility at Allergan Inc., a biomedical company, where she ultimately served as Vice President, Clinical Research and Development for skin care pharmaceuticals.

Over the past 10 years, Dr. Walker was involved in key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac®, Azelex®, Avage®, BOTOX® Cosmetic, Hylaform®, Captique®, JUVEDERM®, Bioenterics®, LAP-BAND®, and Inamed® Silicone gel-filled Breast Implants and Kybella. Dr. Walker received her doctor of medicine (MD) degree and her doctor of philosophy (PhD) degree in Physiology and Biophysics from the University of Iowa. Dr. Walker completed a residency in Dermatology and a research fellowship in the Dermatology Branch of the National Cancer Institute at the National Institutes of Health. Dr. Walker is a board-certified Dermatologist.

Dan Browne is a co-founder of the company and has served as the President, Chief Executive Officer and a member of the board of directors since operations commenced in 2002. Prior to starting Revance, Mr. Browne served as President and Chief Executive Officer of Neomend, Inc., a biologics and biomaterials company; he served as President of Prograft Medical Inc., a developer of peripheral vascular stents and stent-grafts. Previously, Mr. Browne spent more than 16 years in various leadership positions in product development, sales and marketing and business development in the GORE-TEX Medical Products Division of W.L. Gore & Associates, Inc., a global technology company, serving as Business Leader in the Medical Products Division as his final role at the company.

Mark de Souza is an entrepreneur in the rare disease and dermatology space. He is the Executive Chairman of PellePharm, which is developing a topical hedgehog inhibitor for basal cell carcinomas, including those in Gorlin syndrome. He is a Co-founder, President and CEO of Chromaderm, which is developing a topical PKC-beta inhibitor for the treatment of hyperpigmentation disorders. Mark is a Co-founder of MyoTherix, which is developing ion channel modulators for Duchenne muscular dystrophy and Charcot Marie Tooth disease, NFlection Therapeutics, which is developing therapies for neurofibromatosis, Spin Therapeutics, which is developing therapies for orphan pulmonary diseases, FIBRX Tissue Repair, which is developing human recombinant decorin for rare ophthalmological disorders, and SCIDEC Therapeutics, which is developing human recombinant decorin in communicating hydrocephalus. He is a member of the Boards of Directors of these companies.

Previously, Mark was founding President and CEO of Lotus Tissue Repair, which was acquired by Shire for its collagen VII protein replacement therapy for dystrophic epidermolysis bullosa, and VP of Business Development at Dyax Corp., which was acquired by Shire for its hereditary angioedema pipeline that included KALBITOR (ecallantide).

John Dobak, MD, has been involved in new medical innovation for 20 years. He has founded multiple companies in areas as diverse as cardiac arrhythmia ablation and neuromodulation to aesthetic medicine. Over the last four years, Dr. Dobak has been the CEO of DermTech and the founder of two other dermatology companies, 10xBio and @Derma.

Emmanuel Dumont is the founder and CEO of Shade (shade.io), a spin-off of the Jacobs Technion-Cornell Institute in New York that is re-inventing the standard of care in dermatology for photosensitive diseases (skin cancer, autoimmune disorders, etc.). Shade has built a proprietary and differentiable medical-grade wearable ultraviolet sensor that is 30x more accurate than other sensors on the market. The Shade sensor connects to the smartphone, enabling a rich interaction with users and unprecedented data collection about the impact of ultraviolet exposure on health. Dr. Dumont received his PhD in biophysics from Columbia University and his research was peer-reviewed and published in Nature. Prior to his PhD, he worked as an investment banker on Wall Street.

Dr. Lilit Garibyan an Instructor at Harvard Medical School and a physician scientist at the Wellman Center for Photomedicine working in Dr. Rox Anderson's laboratory. Her work focuses on innovative biomedical translational research aimed at identifying novel treatments for dermatologic diseases and beyond. She co-invented and developed a novel platform technology that allows cold to be injected into various tissues within our body for selective targeting lipid rich tissue. Dr. Garibyan is also leading an effort to establish a problem-based innovation model led by clinicians interested in solving clinical problems through the Magic Wand Initiative.

Dr. Garibyan received her BS summa cum laude from University of California Los Angeles, her MD from Harvard Medical School and her PhD from Harvard University in Experimental Pathology/Immunology.

Dr. Giljohann has served as the Chief Executive Officer since November 2013 and been on the board of directors since March 2014. From 2011 to June 2012, Dr. Giljohann served as principal scientist. Prior to that, Dr. Giljohann was the founding scientist of Exicure in 2009.

Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and Spherical Nucleic Acid (SNA™) constructs. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He was also named to the Analytical Scientist's "Top 40 Under 40 Power List" in 2014. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University.

Dr. Girardi is Professor, Vice Chair, and Program Director for the Department of Dermatology of the Yale School of Medicine. He has a broad research and mentoring background in cutaneous immunology, cutaneous carcinogenesis, and cutaneous lymphoma. During more than 15 years leading an NCI-funded research program at Yale, his laboratory is credited with major contributions to our understanding of skin cancer development, and in particular, regarding the communication between keratinocytes and various cells of the immune system. Specifically, the Girardi lab has elucidate roles for gamma-delta T cells, NKG2D ligands, and Langerhans cells in cutaneous biology and skin cancer.

He actively collaborates with the Department of Bioengineering on developing nanoparticle-based skin delivery systems. He also has actively collaborated with the Department of Genetics to identify mutational drivers of cutaneous T cell lymphoma (CTCL), his clinical focus. Dr. Girardi is the Director of the Photopheresis Unit, and investigates the potential modifications to this the treatment for CTCL, cGVHD, scleroderma, and organ transplant rejection.

A serial entrepreneur who has managed and co-founded a number of genomics-based companies including, ProdermIQ, Iceland Genomics and DiThera. Mr. Hosseini's skills in international medical device/diagnostic sales and marketing were developed at Abbott Laboratories, Ortho Clinical Diagnostics (Johnson & Johnson) and Sequenom, where he held executive and management positions in business development, and sales and marketing functions. He has 25+ years of extensive experience working with global biotech, pharmaceutical companies and healthcare providers. He received both his B.Sc. and MBA from the University of British Columbia.

Dr. Brian Kim is Assistant Professor of Dermatology, Anesthesiology, Pathology and Immunology, and Co-Director of the Center for the Study of Itch at Washington University School of Medicine in St. Louis. His laboratory focuses on innate immune mechanisms that underlie skin inflammation and the sensation of itch. Specifically, the Kim Lab identified previously unrecognized contributions of group 2 innate lymphoid cells (ILC2s) and basophils to the pathogenesis of atopic dermatitis (AD). These cells have emerged as critical sources of the type 2 cytokines IL-4, IL-5 and IL-13, which are now among the most important targets for biologic therapy in AD and other allergic disorders.

Current studies in the Kim Lab are aimed at better understanding how innate immune cells and pro-inflammatory mediators specifically regulate the sensation of itch. These studies have broad therapeutic implications for numerous medical disorders that manifest as chronic itch. His research on the immune regulation of AD has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology and the American Society for Clinical Investigation.

Dr. Neil Kirby is an entrepreneur and Chief Executive with 30 years of experience with leading biotechnology companies including Biogen, Genetics Institute / Wyeth, Vertex, TKT / Shire and Stromedix. He is currently a Board member of Edimer Pharmaceuticals, a company developing an innovative treatment for XLHED (X-linked hypohidrotic ectodermal dysplasia) a rare genetic disease characterized by hypothermia, sparse hair, recurrent pneumonia and teeth abnormalities.

In addition, Dr. Kirby is Chairman of the Board of Orphan Technologies, who are committed to developing first-in-class therapeutics for patients suffering from rare diseases. Dr. Kirby has held positions of increasing responsibility in global regulatory affairs, strategic planning, portfolio management, non-clinical development, manufacturing and program management.

During his career, Dr. Kirby has been involved with the development, registration and successful commercial launches of several important therapeutic biopharmaceuticals (including recombinant coagulation factors, cytokines and enzyme replacement therapies). Dr. Kirby received his Ph.D. in the faculty of medicine from the University of London in the UK.

David Lortscher, MD, is a board-certified dermatologist who took leave from his practice in 2014 to start Curology, a skincare-focused teledermatology company where he currently serves as CEO. Dr. Lortscher founded Curology to make prescription acne treatment more accessible, and the company currently serves tens of thousands of patients across the United States.

Alexander Meves, MD, is a consultant in the Department of Dermatology at Mayo Clinic in Minnesota. Dr. Meves joined the staff of Mayo Clinic in 2008 and holds the academic rank of assistant professor of dermatology, Mayo Clinic College of Medicine.

Dr. Meves earned his M.D. at the Heinrich-Heine-University Medical School, Dusseldorf, Germany. During medical school, he also completed a Fulbright Fellowship in cell biology at Harvard Medical School, followed by a brief internship at McKinsey & Company in Munich, Germany, and a Carlo Schmid Fellowship at the World Health Organization in Geneva, Switzerland. He graduated summa cum laude as doctor of medicine (Dr. med.) from his alma mater and received a cash prize for best medical dissertation. He then completed a residency in dermatology and a fellowship in advanced clinical dermatology at Mayo Clinic, which was followed by a 3-year period of postdoctoral training at the Max Planck Institute of Biochemistry in Martinsried near Munich in the laboratory of Dr. Reinhard Fässler.

Dr. Meves' clinical interests are related to skin cancer, specifically melanoma, and skin ageing. His research focuses on the biology of skin cancer and skin ageing, specifically as it relates to the remodeling of connective tissue and the extracellular matrix. He also aims to translate basic research into new and innovative methods to diagnose and treat skin cancer. He has given presentations on his research both domestically and internationally and has authored numerous books, peer-reviewed journal articles, abstracts and other written publications

In recognition of his work, Dr. Meves has received many awards and honors, including the Physician in Training Award, conferred by the American Society of Dermatopathology, the Dermatology Resident Research Award, conferred by the Skin Disease Education Foundation; and the Robert K. Winkelmann Research Award, conferred by Mayo Clinic, and a Career Development Award, conferred by Mayo Clinic.

In addition to his clinical and research activities, Dr. Meves is active in education and mentoring. For example, Dr. Meves trains graduate students and dermatology residents in molecular laboratory techniques.

Dr. Meves is a diplomate of the American Board of Dermatology and is also a member of the American Academy of Dermatology and the Society for Investigative Dermatology.

Dr. Novoa is a clinical assistant professor in the Dermatology and Pathology departments at Stanford University. Board certified in dermatology and dermatopathology, he sees patients and interprets skin biopsies. Dr. Novoa has co-authored over two dozen articles in the scientific literature, including a recent article in Nature featured in Wired, CNN, and The Wall Street Journal. His research interests include the medical applications of artificial intelligence, cutaneous lymphomas, and the side effects of targeted therapies.

A graduate of Harvard College and Harvard Medical School, Dr. Novoa completed his medical internship at Columbia University Medical Center, his dermatology residency at University Hospitals-Case Western Reserve School of Medicine, and his dermatopathology fellowship at the University of Pennsylvania.

Adam Raff, M.D., Ph.D. is a dermatology physician-scientist at the Massachusetts General Hospital. He works on developing point-of-care diagnostics for infectious diseases of the skin, specifically cellulitis, in the laboratory of R. Rox Anderson at the Wellman Center for Photomedicine. He obtained his M.D./Ph.D. with Alpha Omega Alpha honors at the University of Southern California Keck School of Medicine, and his B.S. summa cum laude with Phi Beta Kappa honors at Georgetown University.

Dr. Fernanda H. Sakamoto, MD, PhD is an Assistant Professor in Dermatology at the Harvard Medical School, Wellman Center for Photomedicine, Massachusetts General Hospital. She is a fellow of the AAD, fellow of the ASLMS, a member of the Société Française de Dermatologie; of the Brazilian Society of Dermatology, of the Brazilian Society of Dermatological Surgery, of the Brazilian Group of Melanoma and of the International Society of Dermoscopy.

Dr. Sakamoto’s research interests include PDT, acne, skin cancer, wound healing and laser therapy. Currently her work is focused on the development of new light-based treatments of acne, specially PDT and lasers. She is on the editorial board of Journal of Investigative Dermatology, and has served on the ASLMS Education and International Committees.

Nathan Stasko, PhD, is co-founder, President and Chief Executive Officer and a Director of Novan, Inc (NASDAQ:NOVN). Dr. Stasko has led the transformation of the Company’s nitric oxide platform from the academic benchtop to Phase 3 clinical trials and is considered a leading expert in the field of nitric oxide. He is an inventor of the core Novan technology and of more than 100 patent filings, 19 of which have issued, and has authored several peer-reviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide. Dr. Stasko has led the Company through an initial public offering of its common stock raising $51M, private financings totaling more than $100 million and government grants and contracts totaling $15 million, the latter ultimately resulting in Novan’s national recognition as a Tibbetts Award winner for excellence in Small Business Innovation Research. He has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise, who share his vision to position Novan as a commercially successful leader in the dermatology market.

Additionally, he has fostered a culture of community involvement and charitable giving through the Company’s collective support of a variety of service groups such as the Durham Rescue Mission, North Carolina Food Bank, Toys for Tots Foundation and the Cystic Fibrosis Foundation. Dr. Stasko earned his Ph.D. and an M.S. in chemistry from the University of North Carolina at Chapel Hill and a B.S. in chemistry from Hampden-Sydney College.

Joshua Tam, PhD is a biomedical engineer at the Wellman Center for Photomedicine, where he spearheaded the development of the "tissue copying" approach – the harvesting and grafting of sub-millimeter cores of full-thickness skin tissue, with minimal donor site morbidity. This approach was licensed for commercialization in 2014, and the clinical device is expected to become available in 2017.

Dr. Tamarkin, Chief Executive Officer of Foamix Pharmaceuticals, is a co-founder of the Company and co-inventor of the Foamix Foam and OilGel technologies. In his thirty years of pharmaceutical experience, Dr. Tamarkin held multiple senior management positions at Teva Pharmaceuticals, Portman Pharmaceutical Industries, PowerPaper and TPI.

He holds a PhD degree in chemistry from The Hebrew University of Jerusalem, Israel, and is the inventor of over one hundred patents in the pharmaceutical field.

Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.

Dr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.

In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.

Dr. Walker is an independent consultant and the immediate past director of the Division of Dermatology and Dental Products (DDDP) at the Food and Drug Administration (FDA). From 2006 to 2014 she led this division of over 40 senior physicians, scientists, and staff with responsibilities for review and approval of regulatory applications, including New Drug Applications, Biologics Licensing Applications, Investigational New Drug Applications, labeling supplements, Pediatric Study Plans, Risk Evaluation and Mitigation Strategies, and other regulatory submissions. As division director, responsibilities also included oversight of meetings with industry regarding drug and biologic development programs; management of advisory committee activities; development and implementation of clinical guidance documents, and leading diverse cross-discipline and cross-center teams.

Dr. Walker is a fellow of the American Academy of Dermatology, a member of the American Dermatological Association, and is board certified in Dermatology (1990). She has an active medical license in Maryland. Before going to FDA she was Chief of the Dermatology Section at the Veterans Administration in Martinez, CA.

Dr. Walker's experience includes 18 years at FDA serving in multiple leadership positions across FDA Centers, including medical reviewer, Lead Medical Officer, and Division Director (DDDP) in the Center for Drug Evaluation and Research (CDER); (acting) deputy director in the Division of General, Reconstructive, and Neurological Devices the Center for Devices and Radiologic Health (CDRH); Associate Director for Clinical Affairs in the Office of Nutritional Products, Labeling, and Dietary Supplements; and Director of the Division of Dietary Supplement Programs in the Center for Food Safety and Nutrition (CFSAN).

Dr. Walker received her Bachelor of Science degree from the University of Michigan and her Doctor of Medicine degree from the Uniformed Services University School of Medicine, and served as a medical officer in the US Navy with several ship deployments and service with the US Marine Corps.

Dr. Walker currently provides independent consulting services as Susan J. Walker Consulting, LLC. Susan J Walker Consulting, LLC is a sole proprietorship providing product development and regulatory advice to the pharmaceutical and device industry. The company focus is dermatology. The objective is to assist product developers in moving their products through the approval process to enhance the availability of high quality dermatological products for use by patients and physicians.